trending Market Intelligence /marketintelligence/en/news-insights/trending/6h1gvlsy3eaxa3rtsp8fpg2 content esgSubNav
In This List

Wilson Therapeutics shareholders approve Alexion acquisition

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Wilson Therapeutics shareholders approve Alexion acquisition

Shareholders owning 97.7% of Stockholm's Wilson Therapeutics AB (publ) accepted Alexion Pharmaceuticals Inc.'s acquisition offer.

Relevant regulatory authorities have also approved the deal, Alexion said in a press release.

Settlement of the tendered shares will occur May 30. The remaining shares may be tendered until June 8, and will be settled June 15. There will be compulsory redemption proceedings and the delisting of Wilson Therapeutics' stock from Nasdaq Stockholm afterward.

The New Haven, Conn.-based biopharmaceutical company had agreed to acquire Wilson Therapeutics for about $855 million, to expand its offering in rare diseases.